

1 **TITLE**

2 Defining the role of host biomarkers in the diagnosis and prognosis of childhood pneumonia  
3 – a prospective cohort study

4

5

6 **AUTHORS**

7 Arjun Chandna,<sup>1,2</sup> Yoel Lubell,<sup>2,3</sup> Lazaro Mwandigha,<sup>4</sup> Phattaranit Tanunchai,<sup>3</sup> Asama  
8 Vinitorn,<sup>3</sup> Melissa Richard-Greenblatt,<sup>2,5,6</sup> Constantinos Koshiaris,<sup>4</sup> Direk  
9 Limmathurotsakul,<sup>2,3,7</sup> Francois Nosten,<sup>2,8</sup> Mohammad Yazid Abdad,<sup>2,3</sup> Rafael Perera-  
10 Salazar,<sup>4</sup> Claudia Turner,<sup>1,2</sup> and Paul Turner<sup>1,2</sup>

11

12

13 **AFFILIATIONS**

- 14 1. Cambodia Oxford Medical Research Unit, Angkor Hospital for Children, Siem Reap,  
15 Cambodia
- 16 2. Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, United  
17 Kingdom
- 18 3. Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine,  
19 Mahidol University, Bangkok, Thailand
- 20 4. Department of Primary Care Health Sciences, University of Oxford, Oxford, United  
21 Kingdom
- 22 5. Public Health Ontario, Toronto, Canada
- 23 6. Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto,  
24 Canada

25 7. Department of Tropical Hygiene, Faculty of Tropical Medicine, Mahidol University,  
26 Bangkok, Thailand

27 8. Shoklo Malaria Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae  
28 Sot, Thailand

29

30

### 31 **CORRESPONDING AUTHOR**

32 Dr. Arjun Chandna

33 Cambodia Oxford Medical Research Unit, Angkor Hospital for Children, Siem Reap,

34 Cambodia

35 Email: [arjun@tropmedres.ac](mailto:arjun@tropmedres.ac)

36 Telephone: +855-85-712-586

37

38

### 39 **SHORT TITLE**

40 Host biomarkers in childhood pneumonia

41

42

### 43 **KEY WORDS**

44 Pneumonia; paediatrics; biomarker; endothelium; triage; referral; primary care; low- and

45 middle-income country

46

47

### 48 **ABBREVIATIONS**

49 **ANG-1** = angiotensin-1

- 50 **ANG-2** = angiotensin-2
- 51 **ARI** = acute respiratory infection
- 52 **AUC** = area under the receiver operating characteristic curve
- 53 **AVPU** = Alert Voice Pain Unresponsive
- 54 **CHI3L1** = chitinase-3-like protein-1
- 55 **CI** = confidence interval
- 56 **CRP** = C-reactive protein
- 57 **IL-1ra** = interleukin-1 receptor antagonist
- 58 **IL-6** = interleukin-6
- 59 **IL-8** = interleukin-8
- 60 **IL-10** = interleukin-10
- 61 **IP-10** = inducible protein-10 [CXCL-10]
- 62 **IQR** = interquartile range
- 63 **LAZ** = length-for-age z-score
- 64 **LMIC** = low- and middle-income country
- 65 **LOQ** = limit of quantification
- 66 **LqSOFA** = Liverpool quick Sequential Organ Failure Assessment
- 67 **MAZ** = MUAC-for-age z-score
- 68 **MUAC** = mid-upper arm circumference
- 69 **NLR** = negative likelihood ratio
- 70 **OxTREC** = Oxford Tropical Research Ethics Committee
- 71 **PCT** = procalcitonin
- 72 **PLR** = positive likelihood ratio
- 73 **qSOFA** = quick Sequential Organ Failure Assessment
- 74 **sFlt-1** = soluble fms-like tyrosine kinase-1 [sVEGFR-1]

75 **SpO<sub>2</sub>** = peripheral oxygen saturation

76 **sTNFR-1** = soluble tumour necrosis factor receptor-1

77 **sTREM-1** = soluble triggering receptor expressed on myeloid cells-1

78 **STROBE** = Strengthening the Reporting of Observational Studies in Epidemiology

79 **TMEC** = Tropical Medicine Ethics Committee

80 **USA** = United States of America

81 **WAZ** = weight-for-age z-score

82 **WLZ** = weight-for-length z-score

83 **WHO** = World Health Organization

84

85

86

87 **ABSTRACT**

88

89 *Background*

90 Reliable tools to inform outpatient management of childhood pneumonia in resource-limited  
91 settings are needed. We investigated the value added by biomarkers of host infection  
92 response to the performance of the Liverpool quick Sequential Organ Failure Assessment  
93 score (LqSOFA), for triage of children presenting with pneumonia to a primary care clinic in  
94 a refugee camp on the Thailand-Myanmar border.

95

96 *Methods*

97 900 presentations of children aged  $\leq 24$  months meeting WHO pneumonia criteria were  
98 included. The primary outcome was receipt of supplemental oxygen. We compared  
99 discrimination of a clinical risk score (LqSOFA) to markers of endothelial injury (Ang-1,  
100 Ang-2, sFlt-1), immune activation (CHI3L1, IP-10, IL-1ra, IL-6, IL-8, IL-10, sTNFR-1,  
101 sTREM-1), and inflammation (CRP, PCT), and quantified the net-benefit of including  
102 biomarkers alongside LqSOFA. We evaluated the differential contribution of LqSOFA and  
103 host biomarkers to the diagnosis and prognosis of severe pneumonia.

104

105 *Results*

106 49/900 (5.4%) presentations met the primary outcome. Discrimination of LqSOFA and Ang-  
107 2, the best performing biomarker, were comparable (AUC 0.82 [95% CI 0.76-0.88] and 0.81  
108 [95% CI 0.74-0.87] respectively). Combining Ang-2 with LqSOFA improved discrimination  
109 (AUC 0.91; 95% CI 0.87-0.94;  $p < 0.001$ ), and resulted in greater net-benefit, with 10-30%  
110 fewer children requiring oxygen supplementation incorrectly identified as safe for

111 community-based management. Ang-2 had greater prognostic utility than LqSOFA to  
112 identify children requiring supplemental oxygen later in their illness course.

113

114 *Conclusions*

115 Combining Ang-2 and LqSOFA could guide referrals of childhood pneumonia from  
116 resource-limited community settings. Further work on integration into patient triage is  
117 required.

118

119 **INTRODUCTION**

120

121 Most cases of childhood pneumonia can be successfully managed at home.<sup>1,2</sup> In remote  
122 locations of many low- and middle-income countries (LMICs), where accessing hospital-  
123 level care may incur substantial cost, community-based care is often preferred by families.<sup>3</sup>  
124 However, pneumonia remains the leading cause of death and disability for young children  
125 living in LMICs and clear criteria for the safe outpatient management of pneumonia are  
126 required.<sup>2,4,5</sup>

127

128 The World Health Organization (WHO) recommends that primary care providers use the  
129 presence of ‘Danger Signs’ to determine whether a child with pneumonia requires referral to  
130 hospital.<sup>6,7</sup> However, validity of these signs is unclear and they are affected by substantial  
131 interobserver reliability.<sup>8-10</sup> In 2016, the quick Sequential Organ Failure Assessment  
132 (qSOFA) score was endorsed as a risk stratification tool for adults with suspected infection.<sup>11</sup>  
133 Recently, an age-adapted version (the Liverpool-qSOFA [LqSOFA] score) was developed  
134 specifically for febrile children presenting from the community.<sup>12</sup> In a recent analysis we  
135 demonstrated that the LqSOFA score outperformed two other paediatric severity scores in  
136 Southeast Asian children with acute respiratory infections (ARIs), suggesting that the score  
137 has excellent generalisability and may be practical for use in resource-limited primary care  
138 settings.<sup>13</sup>

139

140 A growing body of evidence indicates that final common pathophysiological pathways  
141 reflecting endothelial injury and immune activation are shared across a range of infectious  
142 diseases,<sup>14,15</sup> including in young children with pneumonia.<sup>16-18</sup> Markers of these pathways  
143 improve performance of clinical severity scores,<sup>19</sup> including qSOFA,<sup>15,20</sup> and consequently

144 they have been proposed as adjuncts to paediatric triage tools.<sup>21</sup> However, it is unknown  
145 whether such markers are elevated sufficiently early in the natural history of childhood  
146 pneumonia for them to be useful for risk stratification in primary care.

147

148 In this study we quantified the value that measurements of biomarkers of the host response to  
149 infection might add to clinical assessment to identify young children with pneumonia who are  
150 suitable for community-based management. We hypothesised that biomarker measurements  
151 would be most useful for prognostication in children not readily identified by clinical severity  
152 scores as requiring referral at the point of presentation.

153

154

155

156

157 **METHODS**

158

159 *Study population*

160 This was a secondary analysis of data collected during a prospective birth cohort study  
161 conducted between September 2007 and September 2010 on the Thailand-Myanmar border.<sup>22</sup>  
162 Children of consenting pregnant women attending a medical clinic for refugees and  
163 internally-displaced people were reviewed at birth and followed-up each month (routine visit)  
164 and during any intercurrent illness (illness visit) until 24 months of age. The few other  
165 medical facilities and restricted movement out of the camp contributed to low attrition rates  
166 and enabled capture of the majority of acute illnesses for which care was sought. All illness  
167 visits meeting WHO pneumonia criteria (cough or difficulty breathing associated with age-  
168 adjusted tachypnoea) were included in this analysis.<sup>23</sup>

169

170

171 *Data collection*

172 Clinical data were measured at presentation by the study team and entered on to structured  
173 case report forms. Heart rate and respiratory rate were measured over one minute. Mental  
174 status was assessed using the Alert Voice Pain Unresponsive (AVPU) scale. Capillary refill  
175 time was measured following the release of gentle pressure on the child's sternum. Serum  
176 samples were collected in plain tubes at presentation. Participants were followed-up each day  
177 during admission to the clinic and at monthly routine visits conducted as part of the  
178 longitudinal birth cohort study.

179

180

181 *Primary and secondary outcomes*

182 The primary outcome was receipt of supplemental oxygen during the illness visit, which was  
183 only indicated if peripheral oxygen saturation (SpO<sub>2</sub>) was < 90%. All staff were trained on  
184 the clinic treatment protocols prior to study commencement. To explore the diagnostic vs.  
185 prognostic value of the biomarkers, the secondary outcomes were SpO<sub>2</sub> < 90% at enrolment  
186 (diagnostic outcome) and receipt of supplemental oxygen within 28 days of the illness visit  
187 (prognostic outcomes).

188

189

#### 190 *Identification and selection of biomarkers*

191 Host biomarkers were selected for analysis following review of the literature and expert  
192 consultation. A range of viral and bacterial pathogens commonly cause pneumonia in  
193 children and it is not possible to obtain a microbiological diagnosis in the vast majority of  
194 cases presenting to primary care. Acknowledging this and recognising therefore that  
195 clinically-useful biomarkers would need to be predictive across a spectrum of infecting  
196 organisms, we prioritised biomarkers implicated in ‘pathogen agnostic’ final common  
197 pathways to severe febrile illness and sepsis, including those reflecting endothelial injury  
198 (angiopoietin-1 [Ang-1], angiopoietin-2 [Ang-2], soluble fms-like tyrosine kinase-1 [sFlt-1;  
199 sVEGFR-1]) and immune activation (chitinase-3-like protein-1 [CHI3L1], interferon-gamma-  
200 inducible protein-10 [IP-10; CXCL-10], interleukin-1 receptor antagonist [IL-1ra],  
201 interleukin-6 [IL-6], interleukin-8 [IL-8], interleukin-10 [IL-10], soluble tumour necrosis  
202 factor receptor-1 [sTNFR-1], soluble triggering receptor expressed on myeloid cells-1  
203 [sTREM-1]).<sup>14-19,24,25</sup> We also included two acute phase proteins (C-reactive protein [CRP]  
204 and procalcitonin [PCT]); although previous studies have found them unhelpful for predicting  
205 the severity of childhood pneumonia,<sup>26</sup> they are measurable using inexpensive commercially-  
206 available rapid tests and familiar to many clinicians.

207 *Laboratory procedures*

208 Serum samples were centrifuged within two hours of collection (ambient temperature, at  
209 3,000 rpm, for 10 minutes) and stored at 2-8°C. Each day, samples were transported using a  
210 cold-chain to the off-site laboratory, aliquoted, and stored at -80°C within 12 hours of  
211 collection. Samples collected on Saturday evening or Sunday were transported at the end of  
212 the working day on Monday ( $\leq 48$  hours after collection). Frozen serum aliquots were thawed  
213 overnight and concentrations of host biomarkers were quantified using the Simple Plex Ella  
214 microfluidic platform (ProteinSimple, San Jose, California, USA).<sup>27</sup> Analytes below the limit  
215 of quantification (LOQ) were assigned a value one-third of the lower limit of the standard  
216 curve (Supplementary Table 1).

217

218

219 *Missing data*

220 Of the 900 included pneumonia presentations, 827 (91.9%; 827/900) had complete data for  
221 all baseline clinical predictor variables. Capillary refill time had the highest proportion of  
222 missingness (7.0%; 63/900; Supplementary Table 2). Median imputation grouped by outcome  
223 status was used to address missing observations.

224

225

226 *Statistical methods*

227 A Lowess smoothing approach was used to explore the relationship between each biomarker  
228 and the primary outcome. We used univariable logistic regression to quantify the ability of  
229 the LqSOFA score and each individual biomarker to discriminate children presenting with  
230 pneumonia who required supplemental oxygen (area under the receiver operating  
231 characteristic curve [AUC]).

232

233 We compared the discrimination of the LqSOFA score to that of the LqSOFA score plus one  
234 biomarker (R package: *pROC*).<sup>28,29</sup> To reduce the risk of multiple testing we limited  
235 comparisons to the five top-performing biomarkers, selected on the basis of their univariate  
236 discrimination, after confirming that none of the biomarker concentrations were strongly  
237 correlated with baseline LqSOFA scores (R package: *polycor*).<sup>30</sup> We used decision curve  
238 analyses (R package: *dcurves*)<sup>31</sup> to determine the net-benefit of including the biomarkers  
239 alongside the LqSOFA score and compared predicted classifications across a range of  
240 clinically-relevant referral thresholds.

241

242 To explore the differential contribution of biomarkers to the diagnosis and prognosis of  
243 severe pneumonia, we used univariable logistic regression to assess the ability of the  
244 LqSOFA score and the five top-performing biomarkers to discriminate children who were  
245 hypoxic at presentation (diagnostic outcome), and to discriminate children who were not  
246 initially hypoxic but whose disease progressed to require supplemental oxygen in the 28 days  
247 following presentation (prognostic outcomes).

248

249 Finally, recognising that a management strategy requiring measurement of a biomarker in  
250 every child presenting with pneumonia would not be practical, we used recursive partitioning  
251 to construct a proof-of-concept management algorithm combining the LqSOFA score and the  
252 top-performing biomarker to identify children who might be safe for community-based  
253 management. We acknowledged that safety and simplicity were paramount for community  
254 triage and specified a loss-matrix of 10:1 and maximum level of tree depth of two (R  
255 package: *rpart*).<sup>32</sup>

256

257 All analyses were conducted in R, version 4.0.2.<sup>33</sup>

258

259

260 *Sample size*

261 No formal sample size calculation was performed for this secondary analysis. All available

262 data were used to maximise power and generalisability of the results.

263

264

265 *Ethics and reporting*

266 Ethical approvals were provided by the Mahidol University Ethics Committee (TMEC 21-

267 023) and Oxford Tropical Research Ethics Committee (OxTREC 511-21). The study is

268 reported in accordance with the Strengthening the Reporting of Observational Studies in

269 Epidemiology (STROBE) guidelines (Supplementary Table 3).<sup>34</sup>

270

271

272

273

274 **RESULTS**

275

276 Between September 2007 and September 2008, 999 pregnant women were enrolled and 965  
277 children were born into the birth cohort. From September 2007 to September 2010 there were  
278 900 presentations from 444 individual children which met the WHO criteria for pneumonia,  
279 had complete information about supplemental oxygen therapy, and had a serum sample  
280 available for analysis (Figure 1).

281

282 Children had been symptomatic for a median of 3 days (interquartile range [IQR] 2 to 5 days)  
283 and fewer than 3% (2.8%; 25/900) had received antibiotics prior to enrolment (Table 1;  
284 Supplementary Table 4). Admission rate to the clinic was 28.4% (256/900). Forty-nine  
285 (5.4%; 49/900) presentations met the primary outcome. The LqSOFA score and biomarkers  
286 reflecting endothelial injury (Ang-2, sFlt-1), immune activation (IL-8, IL-6, IL-1ra), and  
287 inflammation (PCT) were associated with the primary outcome (Table 2; Supplementary  
288 Figure 1;  $p < 0.001$ ).

289

290

291 *Ang-2, sFlt-1, and IL-8 improve discrimination of the LqSOFA score*

292 Ang-2 demonstrated substantially better discrimination than any other biomarker and  
293 comparable discrimination to the LqSOFA score (Table 3). No biomarker outperformed the  
294 clinical LqSOFA score (Supplementary Table 5). The relationships between baseline  
295 biomarker concentrations and the probability of supplemental oxygen requirement are shown  
296 (Supplementary Figure 2).

297

298 As baseline LqSOFA scores and biomarker concentrations were not strongly correlated  
299 (Supplementary Tables 6-7; Supplementary Figure 3) we selected the five most  
300 discriminatory biomarkers and quantified the improvement in discrimination of the LqSOFA  
301 score when combined with each biomarker in turn. Discrimination improved when either  
302 Ang-2, sFlt-1 or IL-8 were combined with LqSOFA (Table 3;  $p < 0.001$  to  $0.001$ ).

303

304

305 *Combining Ang-2 and LqSOFA improves identification of children suitable for community-*  
306 *based management of pneumonia*

307 We recognised that better discrimination does not necessarily translate into greater utility and  
308 acknowledged that the relative value of a true negative (correctly identifying a child who  
309 could be safely managed in the community) and a false negative (misclassifying a child who  
310 would require supplemental oxygen) is context-dependent.<sup>35,36</sup> We used decision curve  
311 analyses to account for this and compared the net-benefit of the LqSOFA score alone to that  
312 of the LqSOFA score combined with either Ang-2, sFlt-1 or IL-8, over a range of clinically-  
313 plausible referral thresholds.<sup>37</sup> At referral thresholds beyond ~8% (a management strategy  
314 equivalent to referring any child in whom the predicted risk of requiring supplemental  
315 oxygen is  $\geq 8\%$ ) addition of Ang-2 to the LqSOFA score provided greater utility than the  
316 LqSOFA score alone (Figure 2). Examining predicted classifications across these referral  
317 thresholds suggested that an algorithm combining Ang-2 and LqSOFA could reduce the  
318 number of children incorrectly identified as safe for community-based management by ~10-  
319 30% compared to the LqSOFA score alone, without substantially increasing the proportion of  
320 unnecessary referrals (Table 4). Addition of neither sFlt-1 nor IL-8 provided greater net-  
321 benefit than the LqSOFA score alone at any referral threshold (Figure 2).

322

323

324 *Differing roles for host biomarkers in the diagnosis and prognosis of severe pneumonia*

325 To explore the differing contributions of host biomarkers to the diagnosis and prognosis of  
326 severe pneumonia we examined the ability of the five most discriminatory biomarkers and  
327 LqSOFA score to distinguish children who were: (a) hypoxic at enrolment ( $SpO_2 < 90\%$ ); (b)  
328 not hypoxic at enrolment but required supplemental oxygen during their illness visit; and (c)  
329 not hypoxic at enrolment but required supplemental oxygen at any time in the 28 days  
330 following enrolment. Discrimination of the LqSOFA score deteriorated for the more  
331 prognostic outcomes, whereas discrimination of the host biomarkers appeared stable (Table  
332 5). Decision curve analyses confirmed Ang-2 to have greater prognostic utility (net-benefit)  
333 than either IL-8 or the LqSOFA score (Supplementary Figure 4).

334

335

336 *An algorithm for the safe outpatient management of childhood pneumonia*

337 We combined the LqSOFA score and Ang-2 to generate a simple proof-of-concept algorithm  
338 for triage of all children presenting with pneumonia (Figure 3). Since sensitivity would  
339 usually be prioritised for community-based triage, we specified the cost of misclassifying a  
340 child who would require supplemental oxygen as 10 times that of the cost of misclassifying a  
341 child who would not, reflecting a pragmatic approximation for the upper limit of the number-  
342 needed-to-refer (NNR; number of children referred in order to identify one child who would  
343 progress to require supplemental oxygen) from a typical resource-limited primary care  
344 setting. The algorithm achieved a negative likelihood ratio (NLR) of 0.28 (sensitivity =  
345 78.1%) and positive likelihood ratio (PLR) of 3.66 (specificity = 78.7%), for the  
346 identification of children suitable for home-based management of pneumonia.

347

348 **DISCUSSION**

349

350 We report the promising performance of Ang-2, a marker of endothelial injury, for risk  
351 stratification of young children presenting with pneumonia to a primary care clinic located  
352 within a refugee camp on the Thailand-Myanmar border. Combining the LqSOFA score with  
353 Ang-2 improved sensitivity of the LqSOFA score alone and resulted in safer identification of  
354 children suitable for community-based management across a range of clinically-plausible  
355 referral thresholds. Furthermore, amongst children not hypoxic at presentation, baseline Ang-  
356 2 concentrations were able to identify those whose illnesses subsequently progressed over the  
357 next 28 days, outperforming other biomarkers and the LqSOFA score.

358

359 The performance of the LqSOFA score is consistent with our broader analysis of the score in  
360 children with ARIs,<sup>13</sup> and comparable to that reported in the original derivation and  
361 validation study.<sup>12</sup> The LqSOFA score is the largest age-adapted version of the widely-  
362 endorsed qSOFA score for adults,<sup>38</sup> and was specifically designed for triaging children  
363 presenting from the community. Unlike other paediatric pneumonia risk scores it uses  
364 routinely collected data, which facilitated external validation in our resource-limited primary  
365 care setting.<sup>39</sup>

366

367 Multiple univariate analyses can emphasise chance findings and hence we elected not to  
368 compare the performance of individual biomarkers to the LqSOFA score in the main analysis.  
369 Policy makers and healthcare workers are most likely to adopt biomarker tests as adjuncts to  
370 clinical risk stratification, although they have been proposed as standalone replacements in  
371 settings with limited capacity for collection of clinical data.<sup>40</sup> In our cohort, whilst Ang-2 and

372 LqSOFA had comparable discrimination, the net-benefit of the LqSOFA score appeared  
373 superior (Supplementary Table 8; Supplementary Figure 5).

374

375 Our results illustrate the critical importance of considering clinical context when evaluating  
376 potential incremental value of biomarkers, rather than relying on summary measures such as  
377 the AUC alone.<sup>36</sup> Although some biomarkers of endothelial injury (Ang-2, sFlt-1) and  
378 immune activation (IL-8) improved the ability of the LqSOFA score to discriminate children  
379 who required supplemental oxygen, only for Ang-2 did this translate into superior clinical  
380 utility (net-benefit).

381

382 Including measurements of Ang-2 alongside the LqSOFA score could make triage of  
383 paediatric pneumonia safer. Sensitivity improved such that ~10-30% fewer children would be  
384 incorrectly identified for community-based management, without increasing the proportion of  
385 inappropriate referrals. However, laboratory tests carry an opportunity cost, especially in  
386 settings with limited resources, and it should be noted that this strategy would require the  
387 measurement of Ang-2 in all children presenting with pneumonia. Whether this is feasible  
388 would depend on many factors, including the availability, durability, turnaround time, and  
389 cost of a point-of-care test for Ang-2. Should such a test become available cost-effectiveness  
390 analyses accounting for differing scenarios would be required before it could be  
391 recommended for use.

392

393 An alternative strategy, perhaps more compatible with the clinical workflow and resources  
394 available in busy LMIC primary care settings, could be to use the easily practicable LqSOFA  
395 score as a screening tool to identify high-risk children with pneumonia, and measure Ang-2  
396 concentrations only in the remaining subset of children not readily identified as requiring

397 referral to hospital by the LqSOFA score. Using this approach, we were able to achieve a  
398 sensitivity of 78.1% (50/64) for identifying children who would require supplemental oxygen  
399 over the 28 days following presentation, whilst maintaining an incorrect-to-correct referral  
400 ratio of 3:1 (i.e., an NNR of four; specificity of 78.7%), and reducing the number of Ang-2  
401 tests performed by more than 20% (179/856). Further efficiencies could be achieved by  
402 converting the points-based LqSOFA score into a clinical prediction model, which would  
403 permit the identification of both low- and high-risk groups who could be adequately risk  
404 stratified without measurement of Ang-2.

405

406 The association between higher concentrations of Ang-2 and supplemental oxygen  
407 requirement has biological plausibility. Ang-2 destabilises the endothelium, increases  
408 microvascular permeability, and is implicated in the pathogenesis of acute lung injury and  
409 sepsis.<sup>14,19,24,41</sup> Previous work has illustrated the prognostic role of Ang-2 in adults with  
410 pneumonia and in hospitalised children with hypoxaemic pneumonia.<sup>16,19</sup> Although this is the  
411 first study to investigate the role of Ang-2 in paediatric pneumonia at the community-level,  
412 endothelial dysfunction has been documented in ambulatory children with mild ARIs.<sup>42</sup>

413

414 Recently, the immune activation marker sTREM-1 has been shown to be prognostic in  
415 hospitalised children with pneumonia and proposed as a possible risk stratification tool.<sup>17,18</sup>  
416 In our cohort, baseline sTREM-1 concentrations were similar in children who did and did not  
417 progress to require supplemental oxygen. As McDonald et al. note, the results of hospital-  
418 based studies cannot be generalised to community settings; in our study most children  
419 (71.6%; 644/900) were managed in the community and only a quarter (26.2%; 236/900) had  
420 severe pneumonia at presentation, compared to over three-quarters of children who had  
421 severe pneumonia at the time sTREM-1 levels were measured in previous hospital-based

422 studies.<sup>17,18</sup> Furthermore, studies of adults with Covid-19 suggest that sTREM-1 may be  
423 useful for predicting mortality but less well-suited for predicting proximal outcomes such as  
424 supplemental oxygen requirement.<sup>43,44</sup>

425

426 This is the largest study investigating the role of markers of endothelial injury and immune  
427 activation in paediatric pneumonia, and the only study to our knowledge conducted at the  
428 community-level. The local circumstances of our cohort enabled us to recruit children at the  
429 first point of contact with the formal health system and follow-up those managed as  
430 outpatients, aspects that are critical for robust evaluation of clinical scores and biomarkers in  
431 primary care.<sup>9</sup> We evaluated a pre-specified panel of biomarkers with mechanistic links to  
432 severe respiratory disease and quantified the value they might add to a validated clinical  
433 score. We adopted an analytical approach which acknowledged that the threshold for home-  
434 based management of pneumonia would vary in different healthcare settings and that there is  
435 an inherent difference between recognising a child who is acutely unwell at the time of  
436 presentation and identifying a child who appears clinically stable but is at risk of subsequent  
437 deterioration.<sup>45</sup>

438

439 Our secondary analysis was limited to the data that were available. Presentations without  
440 serum samples were excluded. These presentations were more likely to have respiratory  
441 distress, altered mental status, and receive supplemental oxygen (Supplementary Table 9),  
442 and thus future studies should assess whether our findings are generalisable to more severe  
443 pneumonia presentations in the community. For the secondary (diagnostic) outcome, 15.3%  
444 (139/905) of presentations were excluded as baseline SpO<sub>2</sub> measurements were missing.  
445 Missingness is unlikely to be at random as measurement of SpO<sub>2</sub> was a prerequisite for  
446 children considered for supplemental oxygen therapy: 89.2% (124/139) of missing values

447 were in outpatients and no presentations missing baseline SpO<sub>2</sub> received supplemental  
448 oxygen. A sensitivity analysis assuming that all presentations missing baseline SpO<sub>2</sub>  
449 measurements were not hypoxic (SpO<sub>2</sub> ≥ 90%) produced almost identical results  
450 (Supplementary Table 10).

451

452 The results of the recursive partitioning analysis will inherently reflect the 10:1 trade-off  
453 between false negatives and false positives specified in the loss-matrix. Whilst this was  
454 informed by our clinical experience of working in resource-limited settings, and is  
455 comparable to approaches taken by other groups,<sup>20,46</sup> it will not apply in all contexts. We  
456 were unable to cross-validate our decision trees and hence the results will be optimistic and  
457 should be viewed as indicative of a framework within which Ang-2 and LqSOFA might be  
458 jointly deployed for triage of childhood pneumonia at the community level.

459

460 Samples collected at weekends were stored at 2-8°C for > 12 hours prior to being transferred  
461 to -80°C. Although most biomarkers are stable at refrigeration temperatures for short periods  
462 following centrifugation,<sup>47</sup> we performed a sensitivity analysis excluding weekend  
463 presentations, which produced similar results (Supplementary Table 11).

464

465 Simple pathogen agnostic algorithms could be particularly impactful in resource-limited  
466 primary care settings where patient management is often syndromic and the infecting  
467 pathogen is usually unknown at the time of initial assessment. We demonstrate that  
468 measurements of Ang-2, a biomarker of endothelial injury, could improve the sensitivity of a  
469 validated clinical score and may enable safer community-based triage of childhood  
470 pneumonia. Combinatorial approaches integrating clinical risk scores and host biomarker  
471 measurements could assist health workers identify children who are acutely unwell at

472 presentation and those who will deteriorate later, enabling earlier and more appropriate  
473 referrals to higher-level care. Future prospective work should focus on validating our findings  
474 and investigate the clinical utility and cost-effectiveness of different strategies for integrating  
475 biomarker measurements into patient assessment and triage.  
476

477 **CONFLICT OF INTEREST DISCLOSURES**

478 The authors have no conflicts of interest relevant to this article to disclose.

479

480

481 **FUNDING/SUPPORT**

482 This research was funded by the UK Wellcome Trust [219644/Z/19/Z]. RPS acknowledges

483 part support from the NIHR Applied Research Collaboration Oxford & Thames Valley, the

484 NIHR Oxford Medtech and In-Vitro Diagnostics Co-operative and the Oxford Martin School.

485 CK is supported by a Wellcome Trust/Royal Society Sir Henry Dale Fellowship

486 [211182/Z/18/Z]. For the purpose of open access, the author has applied a CC BY public

487 copyright license to any Author Accepted Manuscript version arising from this submission.

488

489

490 **DATA SHARING**

491 De-identified, individual participant data from this study will be available to researchers

492 whose proposed purpose of use is approved by the data access committees at the Mahidol-

493 Oxford Tropical Medicine Research Unit. Inquiries or requests for the data may be sent to

494 [datasharing@tropmedres.ac](mailto:datasharing@tropmedres.ac).

495

496

## 497 REFERENCES

- 498 1. Lodha R, Kabra SK, Pandey RM. Antibiotics for community-acquired pneumonia in children. *Cochrane*  
499 *Database Syst Rev* 2013; (6): CD004874.
- 500 2. Wilkes C, Graham H, Walker P, Duke T, group ARIR. Which children with chest-indrawing pneumonia can  
501 be safely treated at home, and under what conditions is it safe to do so? A systematic review of evidence  
502 from low- and middle-income countries. *J Glob Health* 2022; **12**: 10008.
- 503 3. Zhang S, Sammon PM, King I, et al. Cost of management of severe pneumonia in young children:  
504 systematic analysis. *J Glob Health* 2016; **6**(1): 010408.
- 505 4. Marangu D, Zar HJ. Childhood pneumonia in low-and-middle-income countries: An update. *Paediatr*  
506 *Respir Rev* 2019; **32**: 3-9.
- 507 5. McAllister DA, Liu L, Shi T, et al. Global, regional, and national estimates of pneumonia morbidity and  
508 mortality in children younger than 5 years between 2000 and 2015: a systematic analysis. *The Lancet*  
509 *Global Health* 2019; **7**(1): e47-e57.
- 510 6. World Health Organization. Integrated Management of Childhood Illnesses. Geneva, Switzerland; 2014.
- 511 7. World Health Organization. Integrated Community Case Management. Geneva, Switzerland; 2012.
- 512 8. Keitel K, Kilowoko M, Kyungu E, Genton B, D'Acremont V. Performance of prediction rules and guidelines  
513 in detecting serious bacterial infections among Tanzanian febrile children. *BMC Infect Dis* 2019; **19**(1):  
514 769.
- 515 9. Hansoti B, Jenson A, Keefe D, et al. Reliability and validity of pediatric triage tools evaluated in Low  
516 resource settings: a systematic review. *BMC Pediatr* 2017; **17**(1): 37.
- 517 10. Lange S, Mwisongo A, Maestad O. Why don't clinicians adhere more consistently to guidelines for the  
518 Integrated Management of Childhood Illness (IMCI)? *Soc Sci Med* 2014; **104**: 56-63.
- 519 11. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis  
520 and Septic Shock (Sepsis-3). *JAMA* 2016; **315**(8): 801-10.
- 521 12. Romaine S.T, Potter J, Khanijau A, et al. Accuracy of a Modified qSOFA Score for Predicting Critical Care  
522 Admission in Febrile Children. *Pediatrics* 2020; **146**(4): e20200782.
- 523 13. Chandna A, Mwandigha L, Koshariis C, et al. External validation and updating of clinical severity scores to  
524 guide referral of young children with acute respiratory infections in resource-limited primary care  
525 settings. *medRxiv* 2022.
- 526 14. Leligdowicz A, Richard-Greenblatt M, Wright J, Crowley VM, Kain KC. Endothelial Activation: The Ang/Tie  
527 Axis in Sepsis. *Front Immunol* 2018; **9**: 838.
- 528 15. Wright SW, Lovelace-Macon L, Hantrakun V, et al. sTREM-1 predicts mortality in hospitalized patients  
529 with infection in a tropical, middle-income country. *BMC Med* 2020; **18**(1): 159.
- 530 16. Zhang R, Rai U, Ibrahim NBM, et al. Dysregulation of angiotensin-Tie-2 axis in ugandan children  
531 hospitalized with pneumonia. *Cytokine* 2020; **133**: 155175.
- 532 17. Jullien S, Richard-Greenblatt M, Ngai M, et al. Performance of host-response biomarkers to risk-stratify  
533 children with pneumonia in Bhutan. *J Infect* 2022.
- 534 18. McDonald CR, Leligdowicz A, Conroy AL, et al. Immune and endothelial activation markers and risk  
535 stratification of childhood pneumonia in Uganda: A secondary analysis of a prospective cohort study.  
536 *PLoS Med* 2022; **19**(7): e1004057.
- 537 19. Gutbier B, Neuhauss AK, Reppe K, et al. Prognostic and Pathogenic Role of Angiotensin-1 and -2 in  
538 Pneumonia. *Am J Respir Crit Care Med* 2018; **198**(2): 220-31.
- 539 20. Richard-Greenblatt M, Boillat-Blanco N, Zhong K, et al. Prognostic Accuracy of Soluble Triggering Receptor  
540 Expressed on Myeloid Cells (sTREM-1)-based Algorithms in Febrile Adults Presenting to Tanzanian  
541 Outpatient Clinics. *Clin Infect Dis* 2020; **70**(7): 1304-12.
- 542 21. Balanza N, Erice C, Ngai M, Varo R, Kain KC, Bassat Q. Host-Based Prognostic Biomarkers to Improve Risk  
543 Stratification and Outcome of Febrile Children in Low- and Middle-Income Countries. *Front Pediatr* 2020;  
544 **8**: 552083.
- 545 22. Turner C, Turner P, Carrara V, et al. High rates of pneumonia in children under two years of age in a South  
546 East Asian refugee population. *PLoS One* 2013; **8**(1): e54026.
- 547 23. World Health Organization. Integrated Management of Childhood Illnesses. Geneva, Switzerland, 2005.
- 548 24. Parikh SM. Dysregulation of the angiotensin-Tie-2 axis in sepsis and ARDS. *Virulence* 2013; **4**(6): 517-24.
- 549 25. Fuchs A, Gotta V, Decker ML, et al. Cytokine kinetic profiles in children with acute lower respiratory tract  
550 infection: a post hoc descriptive analysis from a randomized control trial. *Clin Microbiol Infect* 2018;  
551 **24**(12): 1341 e1- e7.

- 552 26. Florin TA, Ambroggio L, Brokamp C, et al. Biomarkers and Disease Severity in Children With Community-  
553 Acquired Pneumonia. *Pediatrics* 2020; **145**(6).
- 554 27. Leigdowicz A, Conroy AL, Hawkes M, et al. Validation of two multiplex platforms to quantify circulating  
555 markers of inflammation and endothelial injury in severe infection. *PLoS One* 2017; **12**(4): e0175130.
- 556 28. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the Areas under Two or More Correlated Receiver  
557 Operating Characteristic Curves: A Nonparametric Approach. *Biometrics* 1988; **44**: 837-45.
- 558 29. Robin X, Turck N, Hainard A, et al. pROC: an open-source package for R and S+ to analyze and compare  
559 ROC curves. *BMC Bioinformatics* 2011; **12**(77).
- 560 30. Fox J. polycor: Polychoric and Polyserial Correlations. R package version 0.8-1.; 2022.
- 561 31. Sjoberg DD. dcurves: Decision Curve Analysis for Model Evaluation. R package version 0.3.0. 2022.
- 562 32. Therneau T, Atkinson B. rpart: Recursive Partitioning and Regression Trees. 2019.
- 563 33. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for  
564 Statistical Computing; 2020.
- 565 34. von Elm E, Altman DG, Egger M, Pocock SJ, Gotsche PC, Vandenbroucke JP. The Strengthening the  
566 Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting  
567 Observational Studies. *PLoS Med* 2007; **4**(10).
- 568 35. Fackler JC, Rehman M, Winslow RL. Please Welcome the New Team Member: The Algorithm. *Pediatr Crit  
569 Care Med* 2019; **20**(12): 1200-1.
- 570 36. de Hond AAH, Steyerberg EW, van Calster B. Interpreting area under the receiver operating characteristic  
571 curve. *Lancet Digit Health* 2022; **0**(0).
- 572 37. Vickers AJ, Van Calster B, Steyerberg EW. Net benefit approaches to the evaluation of prediction models,  
573 molecular markers, and diagnostic tests. *BMJ* 2016; **352**: i6.
- 574 38. Eun S, Kim H, Kim HY, et al. Age-adjusted quick Sequential Organ Failure Assessment score for predicting  
575 mortality and disease severity in children with infection: a systematic review and meta-analysis. *Sci Rep*  
576 2021; **11**(1): 21699.
- 577 39. Deardorff KV, McCollum ED, Ginsburg AS. Pneumonia Risk Stratification Scores for Children in Low-  
578 Resource Settings: A Systematic Literature Review. *Pediatr Infect Dis J* 2018; **37**(8): 743-8.
- 579 40. Wright SW, Hantrakun V, Rudd KE, et al. Enhanced bedside mortality prediction combining point-of-care  
580 lactate and the quick Sequential Organ Failure Assessment (qSOFA) score in patients hospitalised with  
581 suspected infection in southeast Asia: a cohort study. *The Lancet Global Health* 2022; **10**(9): e1281-e8.
- 582 41. Hakanpaa L, Sipila T, Leppanen VM, et al. Endothelial destabilization by angiotensin-2 via integrin beta1  
583 activation. *Nat Commun* 2015; **6**: 5962.
- 584 42. Charakida M, Donald AE, Terese M, et al. Endothelial dysfunction in childhood infection. *Circulation* 2005;  
585 **111**(13): 1660-5.
- 586 43. Chandna A, Mahajan R, Gautam P, et al. Host biomarkers reflect prognosis in patients presenting with  
587 moderate Covid-19 – a prospective cohort study *Open Forum Infect Dis* 2022; **0**(0).
- 588 44. Van Singer M, Brahier T, Ngai M, et al. COVID-19 risk stratification algorithms based on sTREM-1 and IL-6  
589 in emergency department. *J Allergy Clin Immunol* 2021; **147**(1): 99-106 e4.
- 590 45. Chandna A, Osborn J, Bassat Q, et al. Anticipating the future: prognostic tools as a complementary  
591 strategy to improve care for patients with febrile illnesses in resource-limited settings. *BMJ Glob Health*  
592 2021; **6**(7).
- 593 46. Erdman LK, Dhabangi A, Musoke C, et al. Combinations of host biomarkers predict mortality among  
594 Ugandan children with severe malaria: a retrospective case-control study. *PLoS One* 2011; **6**(2): e17440.
- 595 47. Chandna A, Richard-Greenblatt M, Tustin R, et al. Practical Methods to Permit the Analysis of Host  
596 Biomarkers in Resource-Limited Settings. *Am J Trop Med Hyg* 2022.

597

598 **TABLE 1. Baseline clinical characteristics of the cohort stratified by primary outcome status.** <sup>a</sup>Respiratory distress defined as head  
599 bobbing, tracheal tug, grunting and/or chest indrawing; <sup>b</sup>abnormal chest auscultation defined as crepitations and/or wheeze; <sup>c</sup>rectal temperature  
600 converted to axillary temperature for neonates and infants. <sup>†</sup>Age-adjusted z-scores were calculated using the R package *z scorer*. For children  
601 admitted to the clinic, weight was measured at the time of presentation (seca scale; precision  $\pm 5$ g for neonates or  $\pm 50$ g after birth). All other  
602 anthropometric data were captured during routine visits and were eligible for inclusion in these analyses according to the following window  
603 periods: height  $\leq 28$  days; MUAC  $\leq 28$  days without intercurrent admission; weight  $\leq 14$  days without intercurrent admission. Median interval  
604 between anthropometric measurement and illness presentation: length = 8 days (IQR 4-12 days); MUAC = 9 days (IQR 4-13 days); weight = 4  
605 days (IQR 0-9 days). \*Missing data: gestation = 3; birthweight = 7; comorbidity = 4; symptom duration = 3; abnormal lung auscultation = 13;  
606 lung crepitations = 15; wheeze = 22; heart rate = 2; respiratory rate = 1; temperature = 1; oxygen saturation = 138; capillary refill time = 63;  
607 mental status = 12; WLZ = 47; WAZ = 46; MAZ = 98; LAZ = 3.  
608

Characteristic	Overall N = 900 <sup>1</sup>	Supplemental oxygen		p-value <sup>2</sup>
		No N = 851 <sup>1</sup>	Yes N = 49 <sup>1</sup>	
<b>Demographics</b>				
Age (months)	10.7 (6.0, 16.3)	10.8 (6.0, 16.4)	7.0 (3.4, 14.9)	0.010
Male sex	456 / 900 (51%)	432 / 851 (51%)	24 / 49 (49%)	0.80
<b>Birth history</b>				
Gestation (weeks)*	39.1 (38.1, 40.0)	39.1 (38.1, 40.0)	38.5 (37.3, 39.5)	0.011
Birthweight (kg)*	2.9 (2.6, 3.2)	2.9 (2.6, 3.2)	2.6 (2.0, 3.1)	0.006

Characteristic	Overall N = 900 <sup>1</sup>	Supplemental oxygen		p-value <sup>2</sup>
		No N = 851 <sup>1</sup>	Yes N = 49 <sup>1</sup>	
<b>Previous medical history</b>				
Number of previous illness visits	4.0 (2.0, 7.0)	4.0 (2.0, 7.0)	3.0 (2.0, 8.0)	0.40
Time since last illness visit (days)	45.0 (15.0, 106.2)	47.0 (17.0, 109.0)	18.0 (1.0, 69.0)	0.002
Known comorbidity*	11 / 896 (1.2%)	7 / 849 (0.8%)	4 / 47 (8.5%)	0.002
<b>History of current illness</b>				
Duration of symptoms (days)*	3.0 (2.0, 5.0)	3.0 (2.0, 5.0)	3.0 (2.0, 5.0)	0.060
Antibiotics prior to presentation	25 / 900 (2.8%)	24 / 851 (2.8%)	1 / 49 (2.0%)	>0.90
<b>Presenting symptoms and signs</b>				
Fever	780 / 900 (87%)	743 / 851 (87%)	37 / 49 (76%)	0.018
Cough	895 / 900 (99%)	846 / 851 (99%)	49 / 49 (100%)	>0.90
Respiratory distress <sup>a</sup>	278 / 900 (31%)	233 / 851 (27%)	45 / 49 (92%)	<0.001
Head bobbing	33 / 900 (3.7%)	15 / 851 (1.8%)	18 / 49 (37%)	<0.001
Tracheal tug	76 / 900 (8.4%)	53 / 851 (6.2%)	23 / 49 (47%)	<0.001
Grunting	14 / 900 (1.6%)	5 / 851 (0.6%)	9 / 49 (18%)	<0.001
Chest indrawing	273 / 900 (30%)	228 / 851 (27%)	45 / 49 (92%)	<0.001

Characteristic	Overall N = 900 <sup>1</sup>	Supplemental oxygen		p-value <sup>2</sup>
		No N = 851 <sup>1</sup>	Yes N = 49 <sup>1</sup>	
Abnormal lung auscultation <sup>b*</sup>	719 / 887 (81%)	676 / 839 (81%)	43 / 48 (90%)	0.12
Crepitations <sup>*</sup>	659 / 885 (74%)	621 / 838 (74%)	38 / 47 (81%)	0.30
Wheeze <sup>*</sup>	338 / 878 (38%)	311 / 830 (37%)	27 / 48 (56%)	0.009
<b>Vital signs</b>				
Heart rate (bpm) <sup>*</sup>				
Neonate	149.0 (143.8, 160.0)	154.0 (147.2, 160.0)	145.0 (140.0, 153.5)	0.70
Infant	140.0 (130.0, 148.0)	140.0 (130.0, 148.0)	144.0 (134.0, 158.0)	0.019
Child	132.0 (124.0, 140.0)	132.0 (124.0, 140.0)	136.0 (128.0, 141.5)	0.20
Respiratory rate (bpm) <sup>*</sup>				
Neonate	67.0 (63.5, 77.0)	63.0 (61.0, 65.5)	78.0 (73.0, 80.5)	0.081
Infant	58.0 (54.0, 60.8)	58.0 (54.0, 60.0)	60.0 (56.0, 64.0)	0.036
Child	50.0 (46.0, 56.0)	50.0 (46.0, 56.0)	58.0 (46.5, 61.5)	0.046
Axillary temperature (°C) <sup>c*</sup>	37.1 (36.4, 37.7)	37.1 (36.4, 37.7)	37.3 (36.5, 38.1)	0.13
Oxygen saturation (%) <sup>*</sup>	95.0 (93.0, 96.0)	95.0 (93.0, 96.0)	88.0 (86.0, 92.0)	<0.001
Capillary refill time > 2 secs <sup>*</sup>	12 / 837 (1.4%)	8 / 792 (1.0%)	4 / 45 (8.9%)	0.003

Characteristic	Overall N = 900 <sup>1</sup>	Supplemental oxygen		p-value <sup>2</sup>
		No N = 851 <sup>1</sup>	Yes N = 49 <sup>1</sup>	
Not alert <sup>*</sup>	116 / 888 (13%)	87 / 842 (10%)	29 / 46 (63%)	<0.001
<b>Anthropometrics</b>				
Weight-for-length z-score (WLZ) <sup>*†</sup>	-0.2 (-0.9, 0.6)	-0.2 (-0.9, 0.6)	-0.4 (-1.7, 0.7)	0.067
Weight-for-age z-score (WAZ) <sup>*†</sup>	-1.0 (-1.9, -0.4)	-1.0 (-1.8, -0.4)	-1.9 (-3.4, -0.4)	<0.001
MUAC-for-age z-score (MAZ) <sup>*†</sup>	0.1 (-0.6, 0.7)	0.1 (-0.5, 0.7)	-1.2 (-2.0, -0.2)	<0.001
Length-for-age z-score (LAZ) <sup>*†</sup>	-1.6 (-2.5, -0.9)	-1.6 (-2.4, -0.8)	-2.5 (-3.0, -1.3)	0.003

<sup>1</sup>Median (IQR); n / N (%)

<sup>2</sup>Wilcoxon rank sum test; Pearson's Chi-squared test; Fisher's exact test

609

610

611 **TABLE 2. Baseline LqSOFA scores and host biomarker concentrations of the cohort, stratified by primary outcome status.**

612

	Overall N = 900 <sup>1</sup>	Supplemental oxygen		p-value <sup>2</sup>
		No N = 851 <sup>1</sup>	Yes N = 49 <sup>1</sup>	
<b>LqSOFA score</b>				
0	713 / 900 (79%)	703 / 851 (83%)	10 / 49 (20%)	<0.001
1	156 / 900 (17%)	128 / 851 (15%)	28 / 49 (57%)	
2	30 / 900 (3.3%)	20 / 851 (2.4%)	10 / 49 (20%)	
3	1 / 900 (0.1%)	0 / 851 (0%)	1 / 49 (2.0%)	
<b>Host biomarkers</b>				
<i>Endothelial injury</i>				
Ang-1 (pg/ml)	33,913.5 (21,938.0, 46,836.5)	33,897.0 (21,849.0, 46,572.0)	35,880.0 (23,177.0, 50,341.0)	0.50
Ang-2 (pg/ml)	1,538.5 (1,187.0, 1,984.8)	1,485.0 (1,164.5, 1,915.5)	2,261.0 (1,792.0, 3,412.0)	<0.001
sFlt-1 (pg/ml)	170.0 (145.0, 196.0)	168.0 (144.0, 193.0)	197.0 (171.0, 231.0)	<0.001
<i>Immune activation</i>				
CHI3L1 (ng/ml)	43.2 (31.0, 61.4)	43.2 (31.1, 60.8)	44.0 (30.0, 67.8)	0.70
IL-1ra (pg/ml)	1,929.5 (1,217.0, 2,949.8)	1,890.0 (1,210.5, 2,794.0)	3,519.0 (1,858.0, 5,136.0)	<0.001
IL-6 (pg/ml)	17.4 (8.9, 36.4)	16.9 (8.7, 34.6)	38.9 (13.8, 70.7)	<0.001

	Overall N = 900 <sup>1</sup>	Supplemental oxygen		p-value <sup>2</sup>
		No N = 851 <sup>1</sup>	Yes N = 49 <sup>1</sup>	
IL-8 (pg/ml)	35.8 (23.8, 52.0)	34.9 (23.1, 51.0)	53.7 (37.0, 82.1)	<0.001
IL-10 (pg/ml)	17.0 (11.2, 28.0)	16.9 (11.0, 27.2)	22.5 (13.5, 38.7)	0.015
IP-10 (pg/ml)	745.0 (441.0, 1,371.0)	742.0 (438.5, 1,350.5)	886.0 (551.0, 1,834.0)	0.064
sTNFR-1 (pg/ml)	1,583.5 (1,345.8, 1,906.0)	1,575.0 (1,341.0, 1,894.0)	1,821.0 (1,545.0, 2,196.0)	0.001
sTREM-1 (pg/ml)	399.5 (315.0, 522.0)	398.0 (313.5, 520.5)	423.0 (345.0, 533.0)	0.20
<i>Acute phase proteins</i>				
CRP (mg/L)	20.4 (7.4, 44.9)	20.1 (7.2, 43.8)	31.0 (7.5, 67.9)	0.20
PCT (pg/ml)	240.0 (176.0, 391.2)	236.0 (173.0, 372.5)	417.0 (248.0, 722.0)	<0.001

<sup>1</sup>Median (IQR); n / N (%)

<sup>2</sup>Wilcoxon rank sum test; Pearson's Chi-squared test; Fisher's exact test

613 **TABLE 3. Ability of the LqSOFA score and host biomarkers to discriminate children**  
 614 **who required supplemental oxygen, and the value added to the clinical LqSOFA score**  
 615 **by the five top-performing biomarkers.**  
 616

Predictor	AUC (95% CI)		p-value <sup>1</sup>
	Univariate	+ LqSOFA	
<b>LqSOFA</b>	–	0.82 (0.76-0.88)	–
<b>Ang-2</b>	0.81 (0.74-0.87)	0.91 (0.87-0.94)	< 0.001
<b>IL-8</b>	0.72 (0.65-0.79)	0.88 (0.85-0.92)	0.001
<b>sFlt-1</b>	0.69 (0.61-0.77)	0.89 (0.86-0.92)	< 0.001
<b>PCT</b>	0.69 (0.62-0.77)	0.78 (0.69-0.86)	0.015
<b>IL-1ra</b>	0.68 (0.59-0.77)	0.80 (0.72-0.88)	0.242
<b>IL-6</b>	0.65 (0.56-0.74)		
<b>sTNFR-1</b>	0.64 (0.55-0.72)		
<b>IL-10</b>	0.60 (0.52-0.69)		
<b>IP-10</b>	0.58 (0.49-0.66)		
<b>sTREM-1</b>	0.56 (0.49-0.63)		
<b>CRP</b>	0.55 (0.46-0.64)		
<b>Ang-1</b>	0.53 (0.44-0.62)		
<b>CHI3L1</b>	0.52 (0.43-0.61)		

<sup>1</sup>DeLong method to compare AUC of LqSOFA vs. AUC of LqSOFA + biomarker.

617


618 **TABLE 4. Predicted classifications at different referral thresholds using the LqSOFA score and the LqSOFA score combined with Ang-**  
 619 **2.** A referral threshold of 5% reflects a management strategy whereby any child with a predicted probability of requiring oxygen  $\geq 5\%$  is  
 620 referred. \*LqSOFA scores converted to predicted probabilities to facilitate comparison with the LqSOFA score + Ang-2; referral thresholds  
 621 (predicted probabilities) approximate to the following LqSOFA scores: 1%  $\approx \geq 0$ ; 5%  $\approx \geq 1$ ; 20%  $\approx \geq 2$ ; 40%  $\approx \geq 3$ .

Referral threshold	Sensitivity (95% CI)	Specificity (95% CI)	Negative Predictive Value (95% CI)	Positive Predictive Value (95% CI)	Negative Likelihood Ratio (95% CI)	Positive Likelihood Ratio (95% CI)	Cases referred (%)	Cases managed in community (%)	Ratio of Incorrect to Correct referrals	Ratio of Correct to Incorrect cases managed in community
<b>LqSOFA score*</b>										
<b>1%</b>	1.00 (NA)	0.00 (NA)	1.00 (NA)	0.05 (0.04-0.07)	0.00 (NA)	1.00 (NA)	900 (100%)	0 (0%)	17 to 1	NA
<b>5%</b>	0.79 (0.67-0.89)	0.83 (0.80-0.85)	0.99 (0.98-0.99)	0.21 (0.15-0.26)	0.25 (0.13-0.40)	4.56 (3.63-5.54)	184 (20.4%)	716 (79.6%)	4 to 1	71 to 1
<b>20%</b>	0.23 (0.13-0.35)	0.98 (0.97-0.99)	0.96 (0.94-0.97)	0.35 (0.18-0.52)	0.79 (0.67-0.90)	9.95 (4.62-16.91)	28 (3.1%)	872 (96.9%)	2 to 1	22 to 1
<b>40%</b>	0.20 (0.00-0.33)	0.98 (0.97-1.00)	0.96 (0.94-0.97)	0.43 (0.31-1.00)	0.82 (0.68-1.00)	Inf (NA)	1 (0.1%)	899 (99.9%)	0 to 1	18 to 1
<b>LqSOFA score + Ang-2</b>										
<b>1%</b>	1.00 (0.91-1.00)	0.20 (0.00-0.59)	1.00 (1.00-1.00)	0.07 (0.05-0.11)	0.00 (0.00-0.13)	1.32 (1.00-2.66)	559 (62.1%)	341 (37.9%)	10 to 1	Inf to 1
<b>5%</b>	0.85 (0.69-0.93)	0.82 (0.76-0.87)	0.99 (0.98-0.99)	0.21 (0.17-0.26)	0.19 (0.09-0.37)	4.73 (3.74-7.50)	202 (22.4%)	698 (77.6%)	4 to 1	77 to 1
<b>20%</b>	0.43 (0.27-0.56)	0.96 (0.95-0.97)	0.97 (0.95-0.98)	0.40 (0.28-0.50)	0.59 (0.45-0.76)	11.73 (7.26-19.28)	58 (6.4%)	842 (93.6%)	2 to 1	23 to 1
<b>40%</b>	0.29 (0.08-0.46)	0.99 (0.97-0.99)	0.96 (0.95-0.97)	0.52 (0.28-0.67)	0.72 (0.55-0.93)	21.28 (7.56-37.98)	22 (2.4%)	878 (97.6%)	1 to 1	23 to 1

622 **TABLE 5. Discrimination of the LqSOFA score and host biomarkers for the diagnosis and prognosis of severe pneumonia.** Children with  
 623 hypoxia ( $\text{SpO}_2 < 90\%$ ) at presentation excluded for assessment of prognostic outcomes. Presentations with missing outcome status excluded:  
 624 Outcome 1 assessed in 766 presentations (734 controls and 32 cases); Outcome 2 assessed in 869 presentations (846 controls and 23 cases);  
 625 Outcome 3 assessed in 827 presentations (789 cases and 38 cases).  
 626

<b>OUTCOME 1 (diagnosis) SpO<sub>2</sub> &lt; 90% at enrolment</b>		<b>OUTCOME 2 (prognosis) Supplemental O<sub>2</sub> during illness visit</b>		<b>OUTCOME 3 (prognosis) Supplemental O<sub>2</sub> ≤ 28 days after enrolment</b>	
<b>Predictor</b>	<b>AUC (95% CI)</b>	<b>Predictor</b>	<b>AUC (95% CI)</b>	<b>Predictor</b>	<b>AUC (95% CI)</b>
<b>LqSOFA</b>	0.85 (0.78-0.91)	<b>Ang-2</b>	0.80 (0.70-0.90)	<b>IL-8</b>	0.75 (0.67-0.82)
<b>Ang-2</b>	0.74 (0.65-0.84)	<b>IL-8</b>	0.75 (0.64-0.85)	<b>Ang-2</b>	0.73 (0.64-0.82)
<b>sFlt-1</b>	0.71 (0.62-0.81)	<b>LqSOFA</b>	0.75 (0.64-0.85)	<b>IL-1ra</b>	0.70 (0.61-0.80)
<b>IL-1ra</b>	0.71 (0.61-0.81)	<b>PCT</b>	0.68 (0.56-0.80)	<b>PCT</b>	0.67 (0.59-0.76)
<b>IL-8</b>	0.70 (0.62-0.77)	<b>IL-1ra</b>	0.66 (0.53-0.79)	<b>LqSOFA</b>	0.66 (0.57-0.74)
<b>PCT</b>	0.69 (0.59-0.78)	<b>sFlt-1</b>	0.60 (0.47-0.73)	<b>sFlt-1</b>	0.65 (0.56-0.75)

627 **FIGURE 1. Eligibility of acute illness visits for inclusion in primary analysis.**




628

629

630

631 **FIGURE 2.**

632 **Utility of the LqSOFA score alone and combined with Ang-2, sFlt-1 or IL-8 for the**  
633 **identification of children suitable for community-based management of pneumonia.** The  
634 net-benefit of the LqSOFA score (pink line) is compared to the LqSOFA score combined  
635 with either Ang-2 (green line), IL-8 (turquoise line), or sFlt-1 (blue line), and a “refer-all”  
636 (red line) and “refer-none” (brown line) approach. A threshold probability of 5% is  
637 equivalent to a management strategy in which any child with a predicted risk of supplemental  
638 oxygen requirement  $\geq 5\%$  is referred (i.e., a scenario where the value of one correct referral is  
639 equivalent to 19 incorrect referrals or a number-needed-to-refer of 20).




640

641

642 **FIGURE 3.**

643 **Triage of childhood pneumonia in resource-limited primary care contexts.** The cost of  
644 misclassifying a child who would require supplemental oxygen was prespecified as 10 times  
645 that of misclassifying a child who would not require supplemental oxygen. Cut-points  
646 selected by recursive partitioning. Percentages indicate proportion of cohort in each terminal  
647 node. O<sub>2</sub> = oxygen.

648



649